ELAN AND BIOGEN IDEC GET CANADIAN APPROVAL FOR TYSABRI

Biogen Idec Canada and Elan Corporation announced Wednesday that following a priority review process, Health Canada has granted approval to TYSABRI (natalizumab) for the treatment of relapsing-remitting multiple sclerosis (MS). TYSABRI is the first in a new therapeutic class of MS treatments (called selective adhesion molecule inhibitors) and has been shown to significantly reduce the rate of MS relapses as well as the progression of disability associated with the illness. Easy Bourse (http://www.easybourse.com/Website/dynamic/News.php?NewsID=66886&lang=fra&NewsRubrique=2)